Novavax is a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases. NVX-CoV2373 is made using Novavax proprietary nanoparticle technology, with Phase 1 clinical trial results expected in July of 2020, and receiving funding from CEPI (Coalition for Epidemic Preparedness Innovations). Matrix-M™ is Novavax’ proprietary adjuvant that is incorporated into the vaccine candidate, in order to enhance the immune response and stimulate high levels of neutralizing antibodies.
The AGC Group is committed to helping prevent the spread of COVID-19 and end this pandemic by playing its role in the manufacture of COVID-19 vaccines and drugs for pharmaceutical companies.
Novavax is a late-stage biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Matrix-M™ is Novavax’ proprietary saponin-based adjuvant incorporated in the vaccines developed by the company to enhance the immune response and stimulate high levels of neutralizing antibodies.
Visit the URL below for more details.